Acipimox Acutely Increases GLP-1 Concentrations in Overweight Subjects and Hypopituitary Patients

CONTEXT: Glucagon-like peptide-1 (GLP-1) is an incretin hormone used therapeutically in T2DM and obesity. The interplay between ambient fatty acids (FFA) and GLP-1, remains unclear. Acipimox suppresses adipose tissue lipolysis via activation of the PUMA-G (aka HCA(2) and GPR109a) receptor. OBJECTIVE...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Endocrinol Metab
Autors principals: Vestergaard, Esben Thyssen, Hjelholt, Astrid Johanneson, Kuhre, Rune E., Møller, Niels, Larraufie, Pierre, Gribble, Fiona M., Reimann, Frank, Jessen, Niels, Holst, Jens Juul, Jørgensen, Jens Otto Lunde
Format: Artigo
Idioma:Inglês
Publicat: 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7212086/
https://ncbi.nlm.nih.gov/pubmed/30726969
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jc.2018-02503
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars